百诚医药 (301096.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

CNY 5.26B

MomentumView details →

1D Return

−3.15%

YTD Return

−23.92%

RSI (14)

41.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

CNY 5.26B

RSI (14)

41.9

MomentumView details →

1D Return

−3.15%

YTD Return

−23.92%

ProfitabilityView details →

Gross Margin

41.61%

Net Margin

−7.24%

EBITDA Margin

9.65%

ROE (TTM)

−2.05%

ROA (TTM)

−1.35%

Asset Turnover

0.19x

GrowthView details →

Revenue YoY

−0.73%

EPS YoY

+62.02%

FCF YoY

+46.36%

Revenue CAGR 3Y

+3.73%

EPS CAGR 3Y

−69.39%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.33x

Current Ratio

1.87x

Quick Ratio

1.67x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

709.72M

Net Income (TTM)

−51.39M

Op. CF (TTM)

−91.47M

Latest newsMore news →

Baicheng Pharmaceutical announced its 2026 first-half results: revenue of 304 million yuan, down 8.40% year-on-year; net profit attributable to shareholders of 1.5977 million yuan, down 48.43% year-on-year; and a plan not to distribute dividends or convert capital reserves.10d ago

Baicheng Pharmaceutical's subsidiary Zhejiang Saimei Pharmaceutical won a bid in the 12th national centralized drug procurement for its sitagliptin and metformin extended-release tablets.25d ago

Similar companies

诺思格301333.SZ 钢研纳克300797.SZ 中机认检301508.SZ 联检科技301115.SZ 博济医药300404.SZ 阿尔特300825.SZ

Latest newsMore news →

Baicheng Pharmaceutical announced its 2026 first-half results: revenue of 304 million yuan, down 8.40% year-on-year; net profit attributable to shareholders of 1.5977 million yuan, down 48.43% year-on-year; and a plan not to distribute dividends or convert capital reserves.10d ago Baicheng Pharmaceutical's subsidiary Zhejiang Saimei Pharmaceutical won a bid in the 12th national centralized drug procurement for its sitagliptin and metformin extended-release tablets.25d ago